ENTRY       D11525                      Drug
NAME        Enfortumab vedotin (USAN);
            Enfortumab vedotin (genetical recombination) (JAN);
            Enfortumab vedotin-ejfv;
            Padcev (TN)
PRODUCT     PADCEV (SEAGEN)
FORMULA     C6642H10284N1742O2063S46
EXACT_MASS  148930.0517
MOL_WEIGHT  149022.148
REMARK      Therapeutic category: 4291
            ATC code: L01FX13
            Product: D11525<JP/US>
EFFICACY    Antineoplastic, Nectin-4 antibody, Tubulin polymerization inhibitor
  DISEASE   Urothelial cancer [DS:H00022]
  TYPE      Antibody-drug conjugate
COMMENT     Treatment of cancers expressing Nectin-4
TARGET      PVRL4 (NECTIN4) [HSA:81607] [KO:K06593]
            TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  PATHWAY   hsa04145(10381+10382+10383+203068+347688+347733+7280+81027+84617)  Phagosome
            hsa04520(81607)  Adherens junction
            hsa04540(10381+10382+10383+203068+347688+347733+7280+81027+84617)  Gap junction
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX13 Enfortumab vedotin
                  D11525  Enfortumab vedotin (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Enfortumab Vedotin
                D11525  Enfortumab vedotin (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D11525  Enfortumab vedotin (USAN); Enfortumab vedotin (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Other
                PVRL4 (NECTIN4)
                 D11525  Enfortumab vedotin (USAN) &lt;JP/US&gt;
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                TUBB
                 D11525  Enfortumab vedotin (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11525
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11525
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11525
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11525
DBLINKS     CAS: 1346452-25-2
            PubChem: 384585501
///
